Woldekidan Haregewoin Bezu, Nxumalo Zandile, Takundwa Mutsa M, Woldesemayat Adugna Abdi, Thimiri Govinda Raj Deepak B
Department of Biotechnology, College of Natural and Applied Science, Addis Ababa Science and Technology University, Addis Ababa, Ethiopia.
Synthetic Nanobiotechnology and Biomachines, Synthetic Biology and Precision Medicine Centre, Council for Scientific and Industrial Research, Pretoria, South Africa.
Methods Mol Biol. 2025;2879:301-313. doi: 10.1007/7651_2024_539.
Conventional approaches for treating tumors encompass chemotherapy, radiotherapy, and surgery. However, these methods come with their limitations when applied in clinical practice. Aptamers are often referred to as "chemical antibodies" and consist of short DNA or RNA molecules, designed to bind to a wide range of targets, including proteins or nucleic acid structures. They exhibit strong affinities and remarkable specificity for their target molecules, making them capable of functioning as therapeutic agents to directly impede tumor cell proliferation. This approach helps minimize the harm to normal cells, thus reducing toxicity through decreased side effects. Here we report the procedure to develop ssDNA aptamer and investigate its ability to inhibit cancer cell proliferation in HeLa and MCF-7 cancer cell lines.
传统的肿瘤治疗方法包括化疗、放疗和手术。然而，这些方法在临床实践中应用时存在局限性。适体通常被称为“化学抗体”，由短的DNA或RNA分子组成，旨在结合多种靶标，包括蛋白质或核酸结构。它们对靶分子表现出强亲和力和显著的特异性，使其能够作为治疗剂直接阻碍肿瘤细胞增殖。这种方法有助于将对正常细胞的损害降至最低，从而通过减少副作用来降低毒性。在此，我们报告了开发单链DNA适体的过程，并研究了其在HeLa和MCF-7癌细胞系中抑制癌细胞增殖的能力。
